National Institutes of Health, Public Health Service, DHHS.
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in: 60/122,953 filed 3/5/99 (Provisional I, DHHS ref. No. E-244-97/2); 60/169,564 filed 12/8/99 (Provisional II, DHHS ref. No. E-244-97/0) and PCT (PCT/US00/05582), filed 3/3/00 and claiming priority to both Provisionals I and II, “Vacuolar-Type (H+) ATPase Inhibiting Compounds, Compositions and Uses Thereof;” and 60/053,784, filed 7/25/97 (DHHS Ref. No. E-244-97/1), converted into PCT/US98/15011 filed 7/23/98, “Antitumor Macrocyclic Lactones, Compositions and Methods of Use”, to Attenuon, L.L.C., having a place of business in San Diego, CA. The aforementioned patent rights have been assigned to the United States of America.
Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 24, 2002, will be considered.
Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Wendy R. Sanhai, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail: firstname.lastname@example.org; Telephone: (301) 496-7056, ext. 244; Facsimile: (301) 402-0220.End Preamble Start Supplemental Information
This invention describes a class of macrocyclic lactones (benzolactone enamides) derived from marine sponges, and which inhibit vacuolar-type (H+) ATPases (V-ATPases). Selective inhibition of V-ATPases may represent an effective means of treating various disease states: Alzheimer's disease, glaucoma and osteoporosis and cancer (via affecting cellular proliferation, angiogenesis, tumor cell invasiveness, metastasis and drug resistance). The compounds have been shown to be active against a specific group of human tumors when tested in the NCI 60-cell line panel. The licensee of these inventions will be required to comport with all applicable federal and country-of-collection policies relating to biodiversity.
The field of use may be limited to the treatment of cancer, angiogenesis-dependent diseases and osteoporosis.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.Start Signature
Dated: March 14, 2002.
Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 02-7057 Filed 3-22-02; 8:45 am]
BILLING CODE 4140-01-P